DeCure's autonomous AMR AI scientist is researching a drug-repurposing hypothesis for coronavirus infectious disease — screening already-approved drugs against its 5-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleCoronavirus infectious disease maps to a 5-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for coronavirus infectious disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
cytochrome P450 family 3 subfamily A member 4 (CYP3A4) — CYP3A4 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet hemdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5VCC · 1.7 Å · ligand PROTOPORPHYRIN IX CONTAINING FE (HEM). Experimental structure, not a prediction.
What the evidence adds up to
A 2020 patent review covering SARS-CoV-1, MERS-CoV and SARS-CoV-2 listed protease inhibitors targeting PLpro, 3CLpro, RNA helicase and Spike protein, along with monoclonal antibodies and interferons, as filed therapeutic agents. The same review noted Chinese folk medicine and its medicinal plants as having reported antiviral properties, but provided no clinical data from human trials for any of these candidates. A separate 2020 overview of drug repurposing for COVID-19 stated that the strategy offers a better risk-versus-reward trade-off because the safety profiles of the drugs are already understood, but did not report any efficacy results.
A 2020 interim management paper reported that clinical trials on repurposed drugs for COVID-19, including hydroxychloroquine, arbidol, remdesivir, favipiravir, lopinavir and ritonavir, have not been entirely successful. The paper noted that these drugs are being used in several countries despite moderate to severe adverse effects, and that the trials suffered from a critical flaw in study design: they were not double-blind and had low sample sizes, a compromise justified by the need to balance scientific rigour against speed. No survival or response rates were given for any of these drugs.
A 2022 paper on rehabilitation in pandemic conditions stated that coronavirus infection was mostly mild to moderate, but severe and lethal cases were observed in about 40 percent of patients. It claimed that if a patient with Covid infection is rehabilitated from the first days of illness and continuity is established, the rate of death and admission to the intensive care unit will be sharply reduced. No specific rehabilitation protocol, sample size or quantitative outcome data were provided. A 2023 review on drug repurposing through anticytokine activity offered no new clinical trial results.
What is still missing are adequately powered, double-blind, placebo-controlled trials for any of the repurposed drugs mentioned, with transparent reporting of mortality and serious adverse events. The rehabilitation claim lacks any controlled evidence or defined intervention. No patient stratification by age, comorbidity or immune status has been tested in a randomised design for these repurposing strategies.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Expert Opinion on Therapeutic Patents · 2020 · 81 citations
SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review
AbstractINTRODUCTION: Coronavirus has been responsible for several virus outbreaks since 2003, caused by SARS-CoV-1, MERS-CoV, and currently SARS-CoV-2 (COVID-19), the causative agent of coronavirus disease in 2019. COVID-19 has become a global public health emergency because of its high virulence and mortality capacity. This patent review aims to provide an overview of the patents that present possible treatments for SARS-CoV-1, SARS-CoV-2 and MERS-CoV. AREAS COVERED: To treat SARS, MERS and SARS-CoV-2, researchers have filed patents for a number of therapeutic agents. Most of the treatments found were protease inhibitors aimed at proteases such as PLpro, 3 CLpro, RNA helicase, and Spike protein, or used monoclonal antibodies and interferons. In addition, the use of Chinese folk medicine and its multitude of medicinal plants with strong antiviral properties was reinforced. Thus, these therapies used in previous epidemics can serve as an aid in the new pandemic by SARS-CoV-2 and be a starting point for new treatments. EXPERT OPINION: The various antiviral alternatives presented in this review offer therapeutic options to fight coronavirus infections. If shown to be effective, these drugs may be extremely important in the current pandemic.
Interim Management of COVID-19 by Repurposed Homeopathic Medicines
AbstractRecent publications focus on coronavirus disease 2019 (COVID-19), a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which has gravely impacted the entire world. It is an enveloped RNA virus arising from the genus betacoronavirus.[1] Owing to the lack of any previous treatment modalities available for COVID-19, clinical and health care experts have resorted to the use of drugs known to be effective against other viral fevers. This emergence of drug repurposing has arisen for several reasons, which can be attributed to the slow pace of new drug discovery along with high-cost involvement.[2] [3] Examples of such repurposed drugs include hydroxychloroquine, arbidol, remdesivir, favipiravir, lopinavir, and ritonavir, and these have now been selected for further testing as potential treatment candidates.[4] However, clinical trials on repurposed drugs for the treatment of COVID-19 have not been entirely successful, though they are being used in several countries despite having moderate to severe adverse effects.[5] [6] A critical flaw in such trials is their study design, which is compromised by the fact that these are not double-blind studies and also have a low sample size; however, the scientific rationale given for conducting such trials is to balance scientific rigor against speed.[7]
Path of Science · 2020 · 2 citations · open access
A Brief Overview of Current Drug Repurposing Approaches for COVID-19 Management
AbstractThis brief overview is intended to shed light on the current drug repositioning (also called drug repurposing) in the therapeutics of the novel coronavirus disease which emerged in 2019 (COVID-19). In this sense, the repositioning drugs for new indications can offer a better risk- versus -reward trade-off when compared to other drug development strategies, given that it makes use of drugs whose safety profile are already understood. Nonetheless, this approach allows healthcare professionals to promptly tackle the disease by investigating readily available drugs against it.
International Healthcare Research Journal · 2020 · 1 citations · open access
The Potential Adverse Reactions of Administering Combination Therapy in Covid-19 Patients
AbstractA definite treatment modality for coronavirus disease 2019 (COVID-19) has still not come into picture. With the rise of COVID-19 pandemic, a few drugs have come into light as empirical treatment for this infection. This review focusses on existing approaches to the treat COVID-19 patients with antimalarial drugs and antibiotics analyzing the adverse reactions and interactions of concomitantly administering these drugs. We will also discuss the possibilities of alternate methods to treat this disease.
Zenodo (CERN European Organization for Nuclear Research) · 2022 · 0 citations · open access
ROLE OF REHABILITATION IN PANDEMIC CONDITIONS
AbstractDespite the tireless research of scientists around the world, we are witnessing the prevalence of coronavirus disease, many questions about the etiology, course, prevention, rehabilitation of the disease remain open. Experiments by health professionals have shown that coronavirus infection was mostly mild to moderate, but severe and lethal cases were observed in about 40 percent of patients. Of course, it was noted that the condition of the patient's immune system, as well as the patient's age, the presence of co-morbidities and harmful habits are of great importance. If a patient with Covid infection is rehabilitated from the first days of his illness and its continuity is established, the rate of not only death but also admission to the intensive care unit of many patients will be sharply reduced [3].
Zenodo (CERN European Organization for Nuclear Research) · 2022 · 0 citations · open access
ROLE OF REHABILITATION IN PANDEMIC CONDITIONS
AbstractDespite the tireless research of scientists around the world, we are witnessing the prevalence of coronavirus disease, many questions about the etiology, course, prevention, rehabilitation of the disease remain open. Experiments by health professionals have shown that coronavirus infection was mostly mild to moderate, but severe and lethal cases were observed in about 40 percent of patients. Of course, it was noted that the condition of the patient's immune system, as well as the patient's age, the presence of co-morbidities and harmful habits are of great importance. If a patient with Covid infection is rehabilitated from the first days of his illness and its continuity is established, the rate of not only death but also admission to the intensive care unit of many patients will be sharply reduced [3].
Clinical Medical Reviews and Reports · 2023 · 0 citations · open access
Drug Repurposing Against Covid-19 Through Anticytokine Activity
AbstractDrug repurposing or repositioning is a well-known strategy that seeks to deploy existing licensed drugs for newer indications and provides the quickest possible transition from bench to clinics for unmet therapeutic needs. Given the current, urgent, and dire need for effective therapies against novel coronavirus-19, this approach is particularly appealing. The present review will focus on the repurposing efficacy of the currently used drugs against COVID-19 that act through anticytokine activity.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
